Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | EED | O75530 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31425844 | 1.00 | TDP1 (0.53) | TDP1OPRM1OPRK1MTNR1AMTNR1B | |
| SCHEMBL5986566 | 0.84 | MTNR1A (0.49) | OPRM1OPRK1MTNR1AMTNR1BEED | |
| SCHEMBL1282582 | 0.84 | OPRM1 (0.48) | OPRM1OPRK1MTNR1AMTNR1BEED | |
| SCHEMBL9550460 | 0.84 | OPRM1 (0.48) | TDP1OPRM1OPRK1MTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL29878326 | 0.83 | OPRM1 (0.47) | OPRM1OPRK1MTNR1AMTNR1BEED | |
| SCHEMBL7250151 | 0.83 | MTNR1A (0.48) | OPRM1OPRK1MTNR1AMTNR1BEED | |
| SCHEMBL9911545 | 0.81 | MTNR1A (0.47) | OPRM1OPRK1MTNR1AMTNR1BEED | |
| SCHEMBL22836921 | 0.78 | OPRM1 (0.49) | OPRM1OPRK1MTNR1AMTNR1BMAPT | |
| SCHEMBL31426029 | 0.78 | MTNR1A (0.47) | OPRM1OPRK1MTNR1AMTNR1B | |
| SCHEMBL21437855 | 0.77 | KDM4E (0.41) | TDP1AKR1B1MAPTALOX15SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294792-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-12-01 | — | — | US | disclosed |
| US-8058425-B2 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-11-15 | — | — | US | disclosed |
| US-8022065-B2 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110207721-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-08-25 | — | — | US | disclosed |
| US-7541368-B2 | 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{3-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-ylmethyl]-phenyl}-urea; use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and tumor necrosis factor (TNF) | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-20090105229-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-04-23 | — | — | US | disclosed |
| US-7491716-B2 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY (US) | 2009-02-17 | — | — | US | disclosed |
| US-7405305-B2 | Pyrrole-2, 5dione derivatives and their used as GSK-3 inhibitors | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1487822-B1 | PYRROLE-2,5-DIONE DERIVATIVES AND THEIR USE AS GSK-3 INHIBITORS | LILLY CO ELI (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1622610-B1 | 1-(2H-PYRAZOL-3-YL)-3-{4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AVENTIS PHARMA INC (US) | 2006-12-20 | — | — | EP | disclosed |
| US-6110947-A | AN ANALGESIC AGENT FOR TREATING STROKE, ABDOMINAL PAIN; AS ANTIINFLAMMATORY, DIURETIC, ANESTHETIC OR NEUROPROTECTIVE AGENTS | PFIZER INC. (US) | 2000-08-29 | — | — | US | disclosed |
| US-6057357-A | USEFUL IN TREATING PAIN, INFLAMMATION, PSORIASIS AND IRRITABLE BOWEL SYNDROME | WARNER-LAMBERT COMPANY (US) | 2000-05-02 | — | — | US | disclosed |
| US-5952369-A | ANALGESIC, TREATMENT FOR STROKE OR ABDOMINAL PAIN ASSOCIATED WITH FUNCTIONAL BOWEL DISEASE | PFIZER INC (US) | 1999-09-14 | — | — | US | disclosed |
| WO-1998049158-A1 | PERIPHERALLY SELECTIVE KAPPA OPIOID AGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998049141-A1 | KAPPA OPIOID AGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| EP-0817772-A1 | PYRROLIDINYL HYDROXAMIC ACID COMPOUNDS AND THEIR PRODUCTION PROCESS | PFIZER INC. (US) | 1998-01-14 | — | — | EP | disclosed |
| WO-1996030339-A1 | PYRROLIDINYL HYDROXAMIC ACID COMPOUNDS AND THEIR PRODUCTION PROCESS | PFIZER INC. (US) | 1996-10-03 | — | — | WO | disclosed |
| EP-0552386-A1 | 2-Amino-3 or 6-methoxycyclohexyl amide derivatives | WARNER-LAMBERT COMPANY (US) | 1993-07-28 | — | — | EP | disclosed |
| US-5051428-A | 2-amino-4 or 5-methoxycyclohexyl amides useful as analgesics | WARNER-LAMBERT COMPANY (US) | 1991-09-24 | — | — | US | disclosed |
| EP-0372466-A2 | 2-Amino-4 or 5-methoxycyclohexyl amides useful as analgesics | WARNER-LAMBERT COMPANY (US) | 1990-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294792-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | TDP1 466/4885OPRM1 3164/4885OPRK1 1639/4885 |
| US-20110207721-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | TDP1 466/4885OPRM1 3164/4885OPRK1 1639/4885 |
| US-20090105229-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | TDP1 466/4885OPRM1 3164/4885OPRK1 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.